Cargando…
Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma
Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a pr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410108/ https://www.ncbi.nlm.nih.gov/pubmed/36005512 http://dx.doi.org/10.3390/md20080509 |
_version_ | 1784775014284787712 |
---|---|
author | Khajeh pour, Sana Mateen, Sameena Pashikanti, Srinath Barrott, Jared J. Aghazadeh-Habashi, Ali |
author_facet | Khajeh pour, Sana Mateen, Sameena Pashikanti, Srinath Barrott, Jared J. Aghazadeh-Habashi, Ali |
author_sort | Khajeh pour, Sana |
collection | PubMed |
description | Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a promising treatment option. To address this shortcoming, we used microfluidics to develop a liposomal delivery system with increased anticancer efficacy. The nano-liposome size was determined by transmission electron microscopy. The jaspine B liposome was tested for its tumor inhibitory efficacy compared to plain jaspine B in in vitro and in vivo studies. The human SS cell line was tested for cell viability using varying jaspine B concentrations. In a mouse model of SS, tumor growth suppression was evaluated during four weeks of treatment (3 times/week). The results show that jaspine B was successfully formulated in the liposomes with a size ranging from 127.5 ± 61.2 nm. The MTT assay and animal study results indicate that jaspine B liposomes dose-dependently lowers cell viability in the SS cell line and effectively suppresses tumor cell growth in the SS animal model. The novel liposome drug delivery system addresses jaspine B’s low bioavailability issues and improves its therapeutic efficacy. |
format | Online Article Text |
id | pubmed-9410108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94101082022-08-26 Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma Khajeh pour, Sana Mateen, Sameena Pashikanti, Srinath Barrott, Jared J. Aghazadeh-Habashi, Ali Mar Drugs Article Sphingomyelin is a cell membrane sphingolipid that is upregulated in synovial sarcoma (SS). Jaspine B has been shown to inhibit sphingomyelin synthase, which synthesizes sphingomyelin from ceramide, a critical signal transducer; however, jaspine B’s low bioavailability limits its application as a promising treatment option. To address this shortcoming, we used microfluidics to develop a liposomal delivery system with increased anticancer efficacy. The nano-liposome size was determined by transmission electron microscopy. The jaspine B liposome was tested for its tumor inhibitory efficacy compared to plain jaspine B in in vitro and in vivo studies. The human SS cell line was tested for cell viability using varying jaspine B concentrations. In a mouse model of SS, tumor growth suppression was evaluated during four weeks of treatment (3 times/week). The results show that jaspine B was successfully formulated in the liposomes with a size ranging from 127.5 ± 61.2 nm. The MTT assay and animal study results indicate that jaspine B liposomes dose-dependently lowers cell viability in the SS cell line and effectively suppresses tumor cell growth in the SS animal model. The novel liposome drug delivery system addresses jaspine B’s low bioavailability issues and improves its therapeutic efficacy. MDPI 2022-08-10 /pmc/articles/PMC9410108/ /pubmed/36005512 http://dx.doi.org/10.3390/md20080509 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khajeh pour, Sana Mateen, Sameena Pashikanti, Srinath Barrott, Jared J. Aghazadeh-Habashi, Ali Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title | Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title_full | Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title_fullStr | Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title_full_unstemmed | Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title_short | Formulation, Characterization, and In Vitro/In Vivo Efficacy Studies of a Novel Liposomal Drug Delivery System of Amphiphilic Jaspine B for Treatment of Synovial Sarcoma |
title_sort | formulation, characterization, and in vitro/in vivo efficacy studies of a novel liposomal drug delivery system of amphiphilic jaspine b for treatment of synovial sarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410108/ https://www.ncbi.nlm.nih.gov/pubmed/36005512 http://dx.doi.org/10.3390/md20080509 |
work_keys_str_mv | AT khajehpoursana formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma AT mateensameena formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma AT pashikantisrinath formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma AT barrottjaredj formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma AT aghazadehhabashiali formulationcharacterizationandinvitroinvivoefficacystudiesofanovelliposomaldrugdeliverysystemofamphiphilicjaspinebfortreatmentofsynovialsarcoma |